We're off to the races!

Aptevo's Ixinity Found To Be Safe In Children Under 12 With Hemophilia B

industry_news_banner
Aptevo’s Ixinity, previously approved for use in people over the age of 12, just received approval for use in children under 12, per their ongoing phase 3 trial. Read the full press release here.

Read more news.

en_USEnglish